Georgia Bio today announced recipients for the Innovation Award. The Innovation Award will be presented to Latha Ganeshan, CEO and Founder of Zywie; Robert Ivarie Ph.D., B.S. of University of Georgia/Synageva; Matthew Lyon, M.D. of Augusta University and David Munn, M.D. of Augusta University.
The Georgia Innovation Award honors the department, institution, company or individuals who are forging new ground by thinking outside traditional paradigms to create some unique technology. The recipients will receive their awards at the Georgia Bio Annual Awards Dinner January 26, 2017, from 6 p.m. to 9 p.m., at the Westin Atlanta Perimeter North. Visit www.gabio.org/awards for more details.
Latha Ganesha
Ms. Ganesha is being recognized for her
leadership at Zywie and the commercialization of an innovative
technology which is revolutionizing cardiac remote monitoring with its
innovative solution that improves patient care and value to the
physician. ZywiePro, the next-generation cardiac remote monitoring
solution, leverages mobile and cloud technology to facilitate detection
of cardiovascular arrhythmias in patients in a more timely, accurate and
cost-effective manner than alternative monitoring solutions allow.
Robert Ivarie
Dr. Ivarie is being recognized as a co-founder
of Avigenics (a.k.a. Synageva.) Based on technologies Dr. Ivarie
invented using transgenic chickens as bioreactors to produce
medically-relevant proteins, Synageva developed rare disease
therapeutics. The company was acquired for over $8 billion and their 1st
drug is on the market in the U.S., Europe and Japan. The company
maintains a significant footprint in Oconee County Georgia.
Matthew Lyon
Dr. Lyon is a Professor of Emergency Medicine
at the Medical College of Georgia at Augusta University. He is being
recognized for his pioneering of several new applications for
ultrasound, including use of ultrasound for volume resuscitation in
critically ill patients, use of ultrasound for respiratory complaints
and for traumatic brain injury assessment. His brain injury assessment
using ultrasound has been both experimentally and clinically oriented
and has received grant funding. He is building collaborations with
industry to bring new devices and techniques to the market for brain
injury assessment.
David Munn
David H. Munn, M.D., is a Professor of
Pediatric Hematology-Oncology at the Medical College of Georgia, Augusta
University, and a member of the Georgia Cancer Center. Dr. Munn’s
long-term and continuing work in cancer immunotherapy reflects the best
traditions of laboratory research, clinical research, industry
partnership, and patient care. He is being recognized for his current
research which focuses on tumor immunology, and molecular mechanisms of
immune suppression and tolerance. Dr. Munn’s laboratory studies the
regulation of T cell activation by tolerogenic dendritic cells and
regulatory T cells (Tregs) in the setting of cancer. A major focus of
the laboratory is the immunoregulatory role of tryptophan metabolism via
the enzyme indoleamine 2,3-dioxygenase (IDO).
For a list of past Georgia Bio award recipients, click here.
Georgia Bio (www.gabio.org) is the state’s life science industry association whose members include pharmaceutical, biotechnology and medical device companies, medical centers, universities and research institutes, government groups and other business organizations involved in the development of life sciences related products and services.
Note to Editors: Credentialed members of the news media are invited to attend. Registration is complimentary. Please contact Maria Thacker (404-920-2042; mthacker@gabio.org).
View source version on businesswire.com: http://www.businesswire.com/news/home/20170117005911/en/